GRTX - Galera Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.28
-0.47 (-4.37%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close10.75
Open10.15
Bid4.75 x 800
Ask10.27 x 1000
Day's Range9.23 - 10.71
52 Week Range5.58 - 19.50
Volume15,808
Avg. Volume31,336
Market Cap255.151M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    All
    News
    Press Releases
    • GlobeNewswire

      Galera Therapeutics Appoints Linda B. West to Board of Directors

      Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of Linda B. West to its board of directors. Additionally, as part of a planned transition, Jason Fuller, Ph.D., will not stand for re-election at Galera’s annual meeting. “Linda is a proven and highly regarded business leader with extensive experience in transforming business operations, as well as spearheading governance, compliance and regulatory activities,” said Mel Sorensen, M.D., President and CEO of Galera.

    • GlobeNewswire

      Galera Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Accomplishments

      - Expanded Lead Product Candidate Avasopasem Manganese into Second Radiation Toxicity Indication - - Presented Data Demonstrating Avasopasem Manganese Maintained Anti-Cancer.

    • GlobeNewswire

      Galera Therapeutics Announces Avasopasem Manganese (GC4419) Maintained Anti-Cancer Benefit of Chemoradiotherapy for Head and Neck Cancer While Substantially Reducing Radiation-Induced Severe Oral Mucositis

      Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced full tumor outcomes results from the two-year follow-up of patients with head and neck cancer treated with avasopasem manganese (GC4419), Galera’s lead product candidate for severe oral mucositis (SOM), in a Phase 2b clinical trial. The results will be presented February 28, 2020, during a late-breaking oral presentation at the 2020 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale, Ariz.

    • GlobeNewswire

      Galera Therapeutics Announces Presentation of Avasopasem Manganese (GC4419) Two-Year Tumor Outcomes Data at 2020 Multidisciplinary Head and Neck Cancers Symposium

      MALVERN, Pa., Feb. 24, 2020 -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of.

    • GlobeNewswire

      Galera Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference

      MALVERN, Pa., Feb. 19, 2020 -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of.

    • GlobeNewswire

      Galera Therapeutics Announces Dosing of First Patient in Phase 2a Clinical Trial of Avasopasem Manganese (GC4419) in Second Indication

      Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the first patient has been dosed in a Phase 2a clinical trial of lead product candidate avasopasem manganese (GC4419) to evaluate its ability to reduce the incidence of radiation-induced esophagitis in patients with lung cancer. The open-label, multi-center trial will evaluate the efficacy of avasopasem manganese, a highly selective small molecule superoxide dismutase (SOD) mimetic, in reducing the incidence of severe (Grade 2 or worse on the NCI Common Terminology Criteria for Adverse Events scale) acute radiation-induced esophagitis in patients with lung cancer receiving chemoradiotherapy.

    • GlobeNewswire

      Galera Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

      - Completed Initial Public Offering of Common Stock That Raised Approximately $58 Million in Net Proceeds - - Progressed Pivotal Clinical Trial of GC4419 in Head & Neck.

    • GlobeNewswire

      Galera Therapeutics Announces Publication of GC4419 Data in the Journal of Clinical Oncology

      Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that full results from the 223-patient, randomized, double-blind Phase 2b clinical trial of lead candidate GC4419 (avasopasem manganese) in patients with locally advanced head and neck cancer have been published in the Journal of Clinical Oncology, a journal of the American Society of Clinical Oncology (ASCO).

    • GlobeNewswire

      Galera Therapeutics Announces Pricing of Initial Public Offering

      Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $12.00 per share, for total gross proceeds of $60.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Galera. All of the common stock is being offered by Galera.